Numerai GP LLC Takes Position in Zoetis Inc. (NYSE:ZTS)

Numerai GP LLC acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,513 shares of the company’s stock, valued at approximately $1,224,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. raised its holdings in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 166 shares in the last quarter. Navigoe LLC purchased a new position in Zoetis during the 4th quarter valued at about $30,000. Murphy & Mullick Capital Management Corp purchased a new stake in Zoetis in the fourth quarter worth about $44,000. Finally, Asset Planning Inc bought a new position in shares of Zoetis during the fourth quarter valued at approximately $58,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 0.9%

Shares of NYSE:ZTS opened at $160.43 on Wednesday. The stock’s 50-day simple moving average is $157.03 and its two-hundred day simple moving average is $165.79. The stock has a market capitalization of $71.42 billion, a price-to-earnings ratio of 29.33, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter last year, the firm posted $1.38 earnings per share. The firm’s revenue was up 1.4% compared to the same quarter last year. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several analyst reports. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. UBS Group reduced their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $212.75.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.